Does Gabapentin Relieve Nerve Pain?
Yes, gabapentin is FDA-approved for postherpetic neuralgia, a type of nerve pain following shingles, where it reduces pain intensity.[1] Clinical trials show it lowers pain scores by 30-50% in about half of patients with this condition, with effects starting within 1-2 weeks at doses of 1800-3600 mg/day.[2]
How Does Gabapentin Work for Nerve Pain?
It binds to voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release like glutamate. This dampens abnormal nerve firing in neuropathic pain without directly affecting pain signals at opioid receptors.[3] It's also used off-label for diabetic neuropathy, spinal cord injury pain, and trigeminal neuralgia, with evidence from randomized trials showing moderate pain relief (number needed to treat around 6-8 for 50% improvement).[4]
How Effective Is It Compared to Placebo or Other Drugs?
Meta-analyses of 37 trials confirm gabapentin provides significant relief over placebo for neuropathic pain, with relative risk reduction of 30-40%.[5] It matches amitriptyline and duloxetine in efficacy for diabetic neuropathy but causes less sedation than tricyclics.[6] Pregabalin, a related drug, is slightly more potent but similar overall.[7]
What Do Real-World Studies and Patient Reports Show?
In practice, 30-50% of neuropathic pain patients achieve meaningful relief, though many need combination therapy.[8] Long-term data from registries like the Neuropathic Pain Scale show sustained benefits for 6-12 months in postherpetic neuralgia, but tolerance can develop, requiring dose adjustments.[9] Patient forums report quick relief for burning pain but mixed results for allodynia (pain from light touch).
Common Side Effects and Who Should Avoid It?
Dizziness (20-30%), somnolence (15-20%), and peripheral edema occur frequently, often leading to 20% dropout rates in trials.[10] Avoid in kidney impairment (requires dose reduction) or with opioids due to respiratory depression risk.[11] No evidence of addiction potential like opioids, but abrupt stops can cause withdrawal anxiety.[12]
When Does It Fail or Alternatives Needed?
It fails in 40-60% of cases, especially central neuropathic pain like multiple sclerosis.[13] Switch to SNRIs (duloxetine), topical capsaicin, or cannabinoids if ineffective. Guidelines recommend it as first- or second-line for peripheral neuropathy.[14]
[1]: FDA Label for Neurontin (gabapentin), 2023. https://www.accessdata.fda.gov/drugsatfdadocs/label/2017/020235s064020882s047_021129s046lbl.pdf
[2]: Rowbotham et al., NEJM, 1998.
[3]: Taylor et al., Anesthesiology, 2018.
[4]: Wiffen et al., Cochrane Review, 2017.
[5]: Moore et al., Pain, 2014.
[6]: Boulanger et al., Can J Neurol Sci, 2007.
[7]: Derry et al., Cochrane, 2019.
[8]: Finnerup et al., Lancet Neurol, 2021.
[9]: Jensen et al., Pain, 2014.
[10]: Backonja et al., JAMA, 1998.
[11]: FDA Warnings, 2022.
[12]: Goodman & Gilman, 13th ed., 2018.
[13]: Finnerup et al., Lancet Neurol, 2016.
[14]: NICE Guidelines, Neuropathic Pain, 2020.